Dr Jess Dyson
| British Society of Gastroenterology guidelines for diagnosis and management of autoimmune hepatitis | 2025 |
|
Dr Jess Dyson
| Editorial: Autoimmune Hepatitis—Could It Be as Easy as Vitamin D? | 2025 |
|
Dr Aaron Wetten Dr Jess Dyson Professor David Jones
| Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? | 2024 |
|
Dr Aaron Wetten Dr Jess Dyson Professor David Jones
| Dynamics of Liver Stiffness Measurement and Clinical Course of Primary Biliary Cholangitis | 2024 |
|
Professor Stuart McPherson Dr Jess Dyson Dr Laura Jopson Dr Steven Masson Professor Quentin Anstee et al. | How effective are experienced hepatologists at staging fibrosis using non-invasive fibrosis tests in patients with metabolic dysfunction-associated steatotic liver disease? | 2024 |
|
Professor Stuart McPherson Dr Jess Dyson Dr Steven Masson Professor Quentin Anstee
| Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply | 2024 |
|
Professor Stuart McPherson Dr Jess Dyson Dr Laura Jopson Dr Steven Masson Professor Quentin Anstee et al. | Letter: Beyond advanced fibrosis—The critical need for assessing NITs performance in identifying F2-F3 fibrosis. Authors' reply | 2024 |
|
Dr Jess Leighton Professor David Jones Dr Jess Dyson Professor Heather Cordell
| Network proximity analysis as a theoretical model for identifying potential novel therapies in primary sclerosing cholangitis | 2024 |
|
Dr Jess Dyson
| Prognostic scores for ursodeoxycholic acid-treated patients predict graft loss and mortality in recurrent primary biliary cholangitis after liver transplantation | 2024 |
|
Lucy Gee Dr Ben Barron-Millar Dr Marco Zaki Dr Saimir Luli Rachel Burgoyne et al. | Anti–Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct–Ligated Mice | 2023 |
|
Dr Jess Dyson Professor David Jones
| Bacterial and metabolic phenotypes associated with inadequate response to ursodeoxycholic acid treatment in primary biliary cholangitis | 2023 |
|
Dr Jess Leighton Dr Lin Lee Wong Dr Anna Goulding Dr Penney Gray Professor David Jones et al. | Patient Priorities in Autoimmune Hepatitis: The Need for Better Treatments, More Education and Challenging Stigma | 2023 |
|
Dr Jess Dyson Dr April Phaw Dr Vinod Hegade Dr George Mells Professor David Jones et al. | UK-Wide Multicenter Evaluation of Second-line Therapies in Primary Biliary Cholangitis | 2023 |
|
Dr Daniel Geh Robyn Watson Gourab Sen Jeremy French John Hammond et al. | COVID-19 and liver cancer: Lost patients and larger tumours | 2022 |
|
Dr Jess Dyson
| Editorial: autoimmune hepatitis and metabolic syndrome-associated disease development—an important question but only part of the answer? | 2022 |
|
Dr Aaron Wetten Dr Jess Dyson Professor David Jones
| Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis | 2022 |
|
Dr Aaron Wetten Dr Laura Ogle Dr George Mells Dr Vinod Hegade Dr Laura Jopson et al. | Neurosteroid Activation of GABA-A Receptors: A Potential Treatment Target for Symptoms in Primary Biliary Cholangitis? | 2022 |
|
Dr Jess Dyson Professor David Jones Professor John Sayer
| Primary biliary cholangitis presenting with Fanconi syndrome: An important phenotype | 2022 |
|
Dr David Adams Dr Jess Dyson
| Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis | 2022 |
|
Abdullah Malik Professor Sanjay Pandanaboyana Gourab Sen Professor Stuart McPherson Dr Jess Dyson et al. | Risk factors for decompensation and death following umbilical hernia repair in patients with end-stage liver disease | 2022 |
|
Dr Aaron Wetten Professor David Jones Dr Jess Dyson
| Seladelpar: an investigational drug for the treatment of early-stage primary biliary cholangitis (PBC) | 2022 |
|
Dr Jess Dyson Professor David Jones
| Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group | 2022 |
|
Professor David Jones Dr Aaron Wetten Dr Ben Barron-Millar Dr Laura Ogle Dr George Mells et al. | The relationship between disease activity and UDCA response criteria in primary biliary cholangitis: A cohort study | 2022 |
|
Dr Jess Dyson Professor David Jones
| Bezafibrate for the Treatment of Cholestatic Pruritus: Time for a Change in Management? | 2021 |
|
Dr Jess Dyson Dr Alasdair Blain Dr Mark Hudson Professor Stephen Rushton Professor David Jones et al. | Geo-epidemiology and environmental co-variate mapping of primary biliary cholangitis and primary sclerosing cholangitis | 2021 |
|
Dr Laura Neilson Dr Louise MacDougall Dr Timothy Hardy Dr David Beaton Dr April Phaw et al. | Implementation of a care bundle improves the management of patients with non-alcoholic fatty liver disease | 2021 |
|
Dr April Phaw Dr Jess Leighton Dr Jess Dyson Professor David Jones
| Managing cognitive symptoms and fatigue in cholestatic liver disease | 2021 |
|
Dr Jess Leighton Dr Jess Dyson Professor David Jones
| Patient ownership of primary biliary cholangitis long-Term management | 2021 |
|
Dr Aaron Wetten Professor David Jones Dr Jess Dyson
| Specific considerations for the management of primary biliary cholangitis: are the drug treatment options good enough? | 2021 |
|
Dr Ben Barron-Millar Dr Laura Ogle Emeritus Professor John Kirby Dr Jeremy Palmer Dr Laura Jopson et al. | The Serum Proteome and Ursodeoxycholic Acid Response in Primary Biliary Cholangitis | 2021 |
|
Dr April Phaw Dr Jess Dyson Professor David Jones
| Understanding Fatigue in Primary Biliary Cholangitis | 2021 |
|
Dr April Phaw Dr Jess Dyson Professor David Jones
| Emerging drugs for the treatment of primary biliary cholangitis | 2020 |
|
Dr Jess Dyson Steven White
| Pregnancy outcomes in women with liver transplants: systematic review and meta-analysis | 2020 |
|
Dr Jess Dyson
| Review article: experimental therapies in autoimmune hepatitis | 2020 |
|
Dr Jess Dyson Professor David Jones
| UDCA prophylaxis for post-transplant PBC recurrence prevention: Time to change practice | 2020 |
|
Dr Jess Dyson Professor David Jones
| British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis | 2019 |
|
Dr Jess Dyson Dr Mark Hudson
| Paediatric to adult liver transition services: the state of play in the UK | 2019 |
|
Dr Jess Dyson Dr Mark Hudson
| Disease burden and costs from excess alcohol consumption, obesity, and viral hepatitis: Fourth report of the Lancet Standing Commission on Liver Disease in the UK | 2018 |
|
Dr Jess Dyson Dr Lin Lee Wong Dr Theophile Bigirumurame Dr Stuart Kendrick Professor David Jones et al. | Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom | 2018 |
|
Dr Jess Dyson Professor David Jones Dr Mark Hudson
| Primary sclerosing cholangitis | 2018 |
|
Dr Jess Dyson Dr Dina Tiniakos Professor David Jones
| The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines | 2018 |
|
Dr Lin Lee Wong Dr Holly Fisher Dr Deborah Stocken Stephen Rice Dr Amardeep Khanna et al. | The Impact of Autoimmune Hepatitis and Its Treatment on Health Utility | 2018 |
|
Dr Jess Dyson
| Adult parenteral nutrition in the North of England: A region-wide audit | 2017 |
|
Professor Stuart McPherson Dr Jess Dyson Dr Mark Hudson
| Editorial: improving in-hospital management of decompensated cirrhosis by a ‘care bundle’ – hope, frustration and lessons to learn. Authors’ reply | 2017 |
|
Dr Jess Dyson Dr Mark Hudson
| New metrics for the Lancet Standing Commission on Liver Disease in the UK | 2017 |
|
Dr Gary Reynolds Dr Lin Lee Wong Professor David Jones Dr Jess Dyson
| Balance between exhausted regulatory T cells and CD161(+) NK cells is crucial in acute AIH pathogenesis | 2016 |
|
Kile Green Dr Laura Jopson Dr Ben Barron-Millar Barbara Innes Sarah Pagan et al. | Early Molecular Stratification of High-risk Primary Biliary Cholangitis | 2016 |
|
Dr Jess Dyson Professor David Jones
| Early Primary Biliary Cholangitis is Characterised by Brain Abnormalities on Cerebral Magnetic Resonance Imaging | 2016 |
|
Dr Jess Dyson Professor Chris Lamb Dr Steven Masson Dr Mark Hudson Dr Christian Dipper et al. | Implementation of a “care bundle” improves the management of patients admitted to hospital with decompensated cirrhosis | 2016 |
|
Dr Jess Dyson Dr Laura Jopson Dr Sheila Waugh Professor Stuart McPherson
| Improving testing for hepatitis B before treatment with rituximab | 2016 |
|
Dr Jess Dyson Dr Dina Tiniakos Professor Stuart McPherson
| Liver toxicity associated with sofosbuvir, an NS5A inhibitor and ribavirin use | 2016 |
|
Dr Vinod Hegade Dr Amardeep Khanna Dr Lucy Walker Dr Lin Lee Wong Dr Jess Dyson et al. | Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score | 2016 |
|
Dr Jess Dyson Professor Stuart McPherson
| Reply to "Liver Failure in Human Immunodeficiency Virus - Hepatitis C Virus Coinfection Treated with Sofosbuvir, Ledipasvir and Antiretroviral Therapy" | 2016 |
|
Professor Stuart McPherson Dr Jess Dyson Dr Mark Hudson
| Response to the NCEPOD report: development of a care bundle for patients admitted with decompensated cirrhosis—the first 24 h | 2016 |
|
Dr Jess Dyson Dr Nina Wilson Dr Laura Jopson Samantha Ducker Dr Deborah Stocken et al. | The inter-relationship of symptom severity and quality of life in 2055 patients with primary biliary cholangitis | 2016 |
|
Dr Lin Lee Wong Dr Stuart Kendrick Professor David Jones Dr Jess Dyson
| UK-AIH - Highlighting the need for standardization of treatment in autoimmune hepatitis | 2016 |
|
Dr Laura Jopson Dr Jess Dyson Professor David Jones
| Understanding and Treating Fatigue in Primary Biliary Cirrhosis and Primary Sclerosing Cholangitis | 2016 |
|
Dr Jess Dyson Dr Jeremy Palmer Dr Lin Lee Wong Dr Stuart Kendrick Professor David Jones et al. | Understanding the importance of pro- and anti-inflammatory cytokines in autoimmune hepatitis | 2016 |
|
Dr Lin Lee Wong Dr Stuart Kendrick Dr Jess Dyson Professor David Jones
| Understanding the unmet need in Autoimmune Hepatitis - The United Kingdom AIH Study (UK-AIH) | 2016 |
|
Dr Jess Dyson Dr Steven Masson Professor Stuart McPherson Professor Derek Manas Dr Mark Hudson et al. | Experience of Using Advagraf in a Single Liver Transplant Centre in the United Kingdom | 2015 |
|
Dr Jess Dyson Dr Ahmed Elsharkawy Professor Chris Lamb Dr Ahmad Al-Rifai Emerita Professor Julia Newton et al. | Fatigue in primary sclerosing cholangitis is associated with sympathetic over-activity and increased cardiac output | 2015 |
|
Kile Green Sarah Pagan Dr Jess Dyson Dr Lucy Walker Dr Laura Jopson et al. | High-risk primary biliary cirrhosis has a distinct molecular signature opening the way for a molecular approach to stratified therapeutics | 2015 |
|
Dr Jess Dyson Dr Steven Masson Professor Stuart McPherson Dr Mark Hudson
| Impact of a Nurse-Led Annual Review Clinic for Liver Transplant Recipients | 2015 |
|
Dr Jess Dyson Professor Chris Lamb Dr Mark Hudson Professor Stuart McPherson
| Implementation and impact of a care bundle for the management of patients with decompensated liver disease | 2015 |
|
Dr Jess Dyson Dr Mark Hudson
| Implementation of the Lancet Standing Commission on Liver Disease in the UK | 2015 |
|
Dr Jess Dyson Professor Stuart McPherson Dr Steven Masson Dr Mark Hudson
| Importance of Health Education in an Annual Review Liver Transplant Clinic in the United Kingdom | 2015 |
|
Dr Jess Dyson Professor Quentin Anstee Professor Stuart McPherson
| Non-alcoholic fatty liver disease: a practical approach to treatment | 2015 |
|
Dr Jess Dyson Professor Derek Mann Professor David Jones
| Novel therapeutic targets in primary biliary cirrhosis | 2015 |
|
Dr Jess Dyson Dr Laura Jopson Professor Stuart McPherson
| Rituximab and hepatitis B: are we doing it right? | 2015 |
|
Dr Jess Dyson Professor David Jones
| Unmet clinical need in autoimmune liver diseases | 2015 |
|
Dr Jess Dyson Dr Mark Hudson Professor Derek Manas Dr Steven Masson
| A Positive Complement Dependent Cytotoxic (CDC) Crossmatch Does Not Impact on Patient Survival or Increase the Risk of Acute Cellular Rejection, or Biliary Strictures after Liver Transplantation | 2014 |
|
Dr Jess Dyson Dr Laura Jopson Samantha Ducker Professor David Jones
| Age at Presentation and Gender are Predictors of Increased Mortality Over Long-Term Follow-Up in Primary Biliary Cirrhosis (PBC) | 2014 |
|
Dr Jess Dyson Professor David Jones
| Diagnosis and Management of Patients with primary biliary cirrchosis | 2014 |
|
Dr Jess Dyson Dr Dipanker Chattopadhyay Rajiv Lochan Jayadeva Dr Imran Patanwala Mike Cole et al. | Hepatocellular cancer: The impact of obesity, type 2 diabetes and a multidisciplinary team | 2014 |
|
Dr Jess Dyson Dr Mark Hudson Professor Stuart McPherson
| Lesson of the month 2: Severe reactivation of hepatitis B after immunosuppressive chemotherapy | 2014 |
|
Dr Jess Dyson Professor Stuart McPherson Professor Quentin Anstee
| Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification | 2014 |
|
Dr Jess Dyson Professor James Mason Dr Matthew Rutter
| Prior hysterectomy and discomfort during colonoscopy: a retrospective cohort analysis | 2014 |
|
Dr Jess Dyson Dr Laura Jopson Samantha Ducker Professor David Jones
| The Impact of Age at Presentation on Symptoms in Primary Biliary Cirrhosis | 2014 |
|
Dr Laura Jopson Dr Jess Dyson Professor David Jones
| The New Epidemiology of Primary Biliary Cirrhosis | 2014 |
|
Dr Jess Dyson Professor Chris Day
| Treatment of Non-Alcoholic Fatty Liver Disease | 2014 |
|
Dr Jeremy Palmer Professor David Jones Dr Jess Dyson Emeritus Professor John Kirby
| Understanding the Mechanisms Underpinning Treatment Non-Response in Primary Biliary Cirrhosis: A Tool for Treatment Stratification | 2014 |
|
Dr Jeremy Palmer Dr Jess Dyson Professor David Jones Emeritus Professor John Kirby
| Understanding the mechanisms underpinning treatment non-response in Primary Biliary Cirrhosis: a tool for treatment stratification | 2014 |
|
Dr Laura Jopson Professor David Jones Dr Jess Dyson
| Younger patients presenting with Primary Biliary Cirrhosis are more likely to have cognitive impairment | 2014 |
|
Dr Jess Dyson Professor Stuart McPherson Professor Quentin Anstee
| Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification | 2013 |
|